NASDAQ:CURX
Curanex Pharmaceuticals Inc
Curanex Pharmaceuticals Inc reported net income of −$4.2M in fiscal 2025. The diluted share count rose 92.3%.Summary generated from Curanex Pharmaceuticals Inc's SEC filings. Latest annual report filed Mar 30, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−72.1%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+92.3%
Financials
| Item | 2024 | 2025 |
|---|---|---|
| Revenue | n/a | n/a |
| Operating income | −0 | −4 |
| Net income | −0 | −4 |
| Free cash flow | n/a | n/a |
Recent filings
- 8-KOther events
Sep 4, 2026 - 8-KAmendment to articles or bylaws
Aug 17, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 14, 2026 - 8-KRegulation FD disclosure
May 14, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 14, 2026 - 8-KOther events
May 7, 2026 - 8-KRegulation FD disclosure
Apr 2, 2026 - 10-KAnnual report for the fiscal year ended Dec 31, 2025
Mar 30, 2026